Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) – Equities researchers at Seaport Global Securities cut their Q4 2017 earnings estimates for shares of Aurinia Pharmaceuticals in a research note issued to investors on Wednesday, according to Zacks Investment Research. Seaport Global Securities analyst V. Bernardino now anticipates that the company will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.05). Seaport Global Securities currently has a “Buy” rating on the stock. Seaport Global Securities also issued estimates for Aurinia Pharmaceuticals’ FY2019 earnings at ($0.24) EPS and FY2020 earnings at ($0.11) EPS.
Aurinia Pharmaceuticals (AUP) traded down C$0.04 during mid-day trading on Friday, reaching C$6.78. The company’s stock had a trading volume of 42,831 shares, compared to its average volume of 76,794. Aurinia Pharmaceuticals has a 52-week low of C$2.75 and a 52-week high of C$14.17.
ILLEGAL ACTIVITY NOTICE: This report was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/12/04/seaport-global-securities-analysts-lower-earnings-estimates-for-aurinia-pharmaceuticals-inc-aup.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.